Kovack Advisors Inc. Acquires Shares of 3,276 Idexx Laboratories (IDXX)

Kovack Advisors Inc. bought a new stake in shares of Idexx Laboratories (NASDAQ:IDXX) during the 1st quarter, according to its most recent filing with the SEC. The fund bought 3,276 shares of the company’s stock, valued at approximately $627,000.

Several other institutional investors have also modified their holdings of IDXX. William Blair Investment Management LLC boosted its position in shares of Idexx Laboratories by 219.1% during the 4th quarter. William Blair Investment Management LLC now owns 728,725 shares of the company’s stock valued at $113,958,000 after acquiring an additional 500,359 shares in the last quarter. Lord Abbett & CO. LLC acquired a new stake in shares of Idexx Laboratories during the 1st quarter valued at about $70,762,000. AGF Investments Inc. boosted its position in shares of Idexx Laboratories by 5,862.3% during the 1st quarter. AGF Investments Inc. now owns 338,001 shares of the company’s stock valued at $64,690,000 after acquiring an additional 332,332 shares in the last quarter. Renaissance Technologies LLC boosted its position in shares of Idexx Laboratories by 18.2% during the 4th quarter. Renaissance Technologies LLC now owns 1,879,804 shares of the company’s stock valued at $293,964,000 after acquiring an additional 290,004 shares in the last quarter. Finally, Carillon Tower Advisers Inc. acquired a new stake in shares of Idexx Laboratories during the 4th quarter valued at about $38,842,000. Institutional investors and hedge funds own 86.31% of the company’s stock.

Several brokerages have recently weighed in on IDXX. Canaccord Genuity reiterated a “positive” rating and set a $215.00 target price on shares of Idexx Laboratories in a research report on Monday, May 7th. Stifel Nicolaus lifted their target price on shares of Idexx Laboratories from $215.00 to $225.00 and gave the company a “buy” rating in a research report on Monday, May 7th. Zacks Investment Research upgraded shares of Idexx Laboratories from a “hold” rating to a “buy” rating and set a $230.00 target price on the stock in a research report on Wednesday, May 30th. Credit Suisse Group lifted their target price on shares of Idexx Laboratories from $209.00 to $228.00 and gave the company an “outperform” rating in a research report on Friday, June 1st. Finally, BidaskClub lowered shares of Idexx Laboratories from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, May 9th. One research analyst has rated the stock with a sell rating and nine have assigned a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $218.43.

In other Idexx Laboratories news, VP Jacqueline Studer sold 475 shares of the business’s stock in a transaction dated Wednesday, May 30th. The shares were sold at an average price of $209.98, for a total value of $99,740.50. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director William T. End sold 9,470 shares of the business’s stock in a transaction dated Thursday, May 10th. The shares were sold at an average price of $208.36, for a total transaction of $1,973,169.20. Following the completion of the transaction, the director now owns 31,786 shares in the company, valued at $6,622,930.96. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 11,571 shares of company stock worth $2,405,215. Company insiders own 2.56% of the company’s stock.

Idexx Laboratories opened at $222.58 on Thursday, Marketbeat.com reports. The stock has a market capitalization of $19.20 billion, a price-to-earnings ratio of 67.86, a PEG ratio of 2.62 and a beta of 0.64. Idexx Laboratories has a 12 month low of $146.09 and a 12 month high of $224.50. The company has a current ratio of 0.96, a quick ratio of 0.72 and a debt-to-equity ratio of -12.43.

Idexx Laboratories (NASDAQ:IDXX) last released its quarterly earnings results on Friday, May 4th. The company reported $1.01 EPS for the quarter, beating the Zacks’ consensus estimate of $0.92 by $0.09. The firm had revenue of $537.60 million for the quarter, compared to analyst estimates of $525.14 million. Idexx Laboratories had a net margin of 13.87% and a negative return on equity of 530.24%. The company’s revenue for the quarter was up 16.4% compared to the same quarter last year. During the same period in the previous year, the business earned $0.77 earnings per share. research analysts predict that Idexx Laboratories will post 4.17 earnings per share for the current fiscal year.

Idexx Laboratories Company Profile

IDEXX Laboratories, Inc, together with its subsidiaries, develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. It operates through Companion Animal Group; Water Quality Products; Livestock, Poultry and Dairy; and Other segments.

Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Idexx Laboratories (NASDAQ:IDXX).

Institutional Ownership by Quarter for Idexx Laboratories (NASDAQ:IDXX)

Receive News & Ratings for Idexx Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Idexx Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit